Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Golden Cariboo (CSE:GCC) (OTC:GCCFF) Unlocks Cariboo Gold Potential (click to learn more) An Emerging Name in Cannabis: HERB (click to learn more) AI-Driven Wellness Play on the CSE (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Merck and Co Inc MRK

Healthcare Drug Manufacturers - Major
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSE:MRK)

Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

Business Wire 15 hours ago

KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX(TM) (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

Business Wire 1 day ago

Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants

Canada NewsWire 7 days ago

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

Business Wire 9 days ago

Merck Announces Second-Quarter 2026 Dividend

Business Wire January 27, 2026

Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

ACCESS Newswire January 20, 2026

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX(TM) (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC

Business Wire January 7, 2026

Merck to Complete Acquisition of Cidara Therapeutics

Business Wire January 7, 2026

Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3

Business Wire January 7, 2026
View More News ››

Opinion & Analysis (NYSE:MRK)

ArQule Shares Double on Proposed $2.7 Billion Tender Offer from Merck

Streetwise Reports December 10, 2019

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

Streetwise Reports October 4, 2019

Possible 'best-in-class' alzheimer's drug candidate offers 'disruptive' potential

The Life Sciences Report September 21, 2017

Why the election is not as relevant to drug stocks as you might believe

The Life Sciences Report November 4, 2016

Circling the globe for uncommon biotech opportunities

The Life Sciences Report February 18, 2016

Eight ways to leverage the small-cap biotech bull market: Ajay Tandon and Jay Albany of SeeThruEquity

Gail Dutton October 30, 2015
View More Opinion ››

Bullboard Posts (NYSE:MRK)

Keytruda SC: Big Win or Overhyped?

Keytruda’s SC version is a huge step forward—faster for patients and clinics. But will it hit margins for infusion centers? Oncology...
TradeVision2001 - November 27, 2024

Merck beats earnings expectations (MRK)

601 Views Apr 25, 2024 CNBC's Joe Kernen reports on the company's quarterly earnings results. Merck beats earnings...
Betteryear2 - April 26, 2024

Merck Announces First-Quarter 2024 Financial Results (MRK)

April 25, 2024 06:30 AM Eastern Daylight Time RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the...
Betteryear2 - April 26, 2024

Fear of recession overblown

https://mail.google.com/mail/u/0/#inbox/FMfcgzGpGdlhJzgczCNrqdzVqkFjpqbV
Goodtoreadthis1 - June 27, 2022

ONE DRUG PILL WIPES OUT COVID 19!

India's Ivermectin Blackout - Part V: The Secret Revealed ...   Sep 27, 2021 · By September 12, 2021...
zeropointenergy - October 6, 2021

Share Price

Surprised the share price didn't pop more than it did given the news release.
anjz661 - October 3, 2021
View more Bullboard ››

Geodrill Limited

Geodrill Limited

Geodrill Limited, together with its subsidiaries, provides mineral exploration drilling services to the mining companies in ...
View More »

Podcasts